2型糖尿病患者中SGLT2抑制剂与DPP4抑制剂相关的肾结石风险:一项目标试验模拟研究
基于韩国国民健康保险服务数据库的队列研究,比较2型糖尿病起始SGLT2抑制剂与DPP4抑制剂者的肾结石风险。在无结石者和有结石者中,SGLT2抑制剂组肾结石风险均低于DPP4抑制剂组。
要点
- 平均随访654天,SGLT2抑制剂组肾结石发生率0.65/100人年,DPP4抑制剂组1.12/100人年。
- 总体HR 0.54(95%CI 0.50-0.57),IRD -0.46(95%CI -0.21至-0.52)。
- 无结石者HR 0.43,有结石者HR 0.64;有结石者绝对风险降低更大。
核心结论
- 在无结石者和有结石者中,SGLT2抑制剂与DPP4抑制剂相比肾结石风险更低。
- 尽管无结石者的相对风险降低更大,但有结石者的绝对风险降低更大。
研究设计与样本
- 使用2010-2021年韩国国民健康保险服务数据库的基于人群的队列研究。
- 比较SGLT2抑制剂与DPP4抑制剂的起始者。
- 在无结石者和有结石者中分别进行1:1倾向评分匹配。
- 合并和无结石者及有结石者各自的匹配对数分别为17,006对、105,378对和11,628对。
主要发现
- 平均随访654天,SGLT2抑制剂组肾结石发生率为0.65/100人年,DPP4抑制剂组为1.12/100人年。
- 总体HR 0.54(95%CI 0.50-0.57),IRD -0.46(95%CI -0.21至-0.52)。
- 无结石者中HR 0.43(95%CI 0.39-0.48),IRD -0.32(95%CI -0.27至-0.36)。
- 有结石者中HR 0.64(95%CI 0.59-0.69),IRD -2.26(95%CI -1.77至-2.76)。
- 骨关节炎就诊的阴性对照结局关联接近零。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aim to compare the risk of nephrolithiasis among type 2 diabetes patients who initiated sodium-glucose cotransporter 2 inhibitors (SGLT2is) versus dipeptidyl peptidase 4 inhibitors (DPP4is), individually within stone never- and ever-formers. RESEARCH DESIGN AND METHODS: Using the 2010-2021 Korea National Health Insurance Service database, we conducted a population-based cohort study, comparing initiators of SGLT2is versus DPP4is. The primary outcome was incident nephrolithiasis. Osteoarthritis encounters served as a negative control outcome. After 1:1 propensity score (PS) matching in stone never- and ever-formers, pooled and individual hazard ratios (HRs), incidence rate difference (IRD), and 95% CIs were reported. Subgroup analyses by sex, age, thiazide co-use, and baseline cardiovascular risk were done. RESULTS: The 17,006 PS-matched pairs of SGLT2i and DPP4i initiators were pooled from stone never-formers (105,378 pairs) and ever-formers (11,628 pairs). Over a mean of 654 days, the risk of nephrolithiasis was lower in SGLT2i initiators than in DPP4i initiators: 0.65 vs. 1.12 events per 100 person-years, HR 0.54 (95% CI, 0.50-0.57), IRD -0.46 (95% CI, -0.21 to -0.52). Among never-formers, the HR was 0.43 (95% CI, 0.39-0.48) and IRD was -0.32 (95% CI, -0.27 to -0.36). Among ever-formers, the HR was 0.64 (95% CI, 0.59-0.69) and IRD was -2.26 (95% CI, -1.77 to -2.76). Near-null associations were found for osteoarthritis encounters. Results were consistent across subgroups. CONCLUSIONS: We found a lower risk of nephrolithiasis associated with SGLT2is versus DPP4is in stone never- and ever-formers. Despite a greater relative risk reduction in the former, the absolute risk reduction was greater in the latter.
引用
- Shin A, Shin JY, Kang EH, et al. Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study. Diabetes Care. 2025. PMID: 39666579. doi:10.2337/dc24-1652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。